Drug Trial News

RSS

Eplerenone may also reduce risk of heart failure, shows REMINDER trial

The prescription drug eplerenone appears to reduce the risk of cardiovascular mortality and heart failure after a heart attack by more than one-third, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

STREAM trial: Treatment with tenecteplase before hospital transfer benefits some

A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

RELAX study finds no beneficial effects of erectile dysfunction drug for diastolic heart failure

Despite high expectations for a commonly used erectile dysfunction drug to treat patients with diastolic heart failure, no beneficial effects were found in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.

12 Mar 2013

Cangrelor solidly outperforms clopidogrel during percutaneous coronary intervention

The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

12 Mar 2013

Cangrelor more effective than clopidogrel in preventing blood clots

A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures.

12 Mar 2013

High-dose rosuvastatin reduces acute kidney injury caused by imaging dye in ACS patients

High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

12 Mar 2013

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA.

12 Mar 2013

Results from Orion Pharma’s ORM-12741 phase IIa study on AD

A new drug may improve memory problems in people with moderate Alzheimer's disease, according to a phase IIa study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013. The drug is called ORM-12741.

12 Mar 2013

Addition of niacin to statin does not improve HDL function

While two large clinical trials recently showed that adding niacin to statin therapy failed to improve clinical outcomes despite a significant increase in HDL-C levels, little is known about exactly why the increased HDL-C levels did not reduce the risk of cardiovascular events, including heart attack and stroke.

12 Mar 2013

NIH-sponsored comparative trial evaluates benefits of combination therapy and monotherapy in MS

People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center.

12 Mar 2013

$Sildenafil does not improve exercise capacity in HF patients with preserved ejection fraction$

Sildenafil does not improve exercise capacity in HF patients with preserved ejection fraction

Among patients with heart failure with preserved ejection fraction (a measure of heart function), administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status, according to a study published online by JAMA.

12 Mar 2013

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its Japanese subsidiary, Sosei Co., Ltd., has initiated a Phase III trial for SO-1105 for the treatment of oropharyngeal candidiasis.

12 Mar 2013

Combination of INF and glatiramer acetate does not reduce MS progression

A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together.

12 Mar 2013

Pitavastatin may reduce risk of heart attack, stroke and death in patients with high cholesterol

Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option, according to a new study by researchers from the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City.

12 Mar 2013

$Sildenafil does not help heart failure patients with preserved ejection fraction$

Sildenafil does not help heart failure patients with preserved ejection fraction

A commonly used erectile dysfunction drug, sildenafil, doesn't help patients who have heart failure with preserved ejection fraction, a condition in which the heart's lower chambers are stiff and cannot relax and fill fully between beats.

12 Mar 2013

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

12 Mar 2013

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza or flu for short is caused by a family of viruses, which can be called influenza A or influenza B. Influenza A viruses are found in humans, animals – like swine and horses- and mostly aquatic birds. Influenza B is only found in humans.

11 Mar 2013

Drug Trial News

Eplerenone may also reduce risk of heart failure, shows REMINDER trial

STREAM trial: Treatment with tenecteplase before hospital transfer benefits some

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

RELAX study finds no beneficial effects of erectile dysfunction drug for diastolic heart failure

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Cangrelor solidly outperforms clopidogrel during percutaneous coronary intervention

Cangrelor more effective than clopidogrel in preventing blood clots

High-dose rosuvastatin reduces acute kidney injury caused by imaging dye in ACS patients

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Results from Orion Pharma’s ORM-12741 phase IIa study on AD

Addition of niacin to statin does not improve HDL function

NIH-sponsored comparative trial evaluates benefits of combination therapy and monotherapy in MS

Sildenafil does not improve exercise capacity in HF patients with preserved ejection fraction

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

Combination of INF and glatiramer acetate does not reduce MS progression

Pitavastatin may reduce risk of heart attack, stroke and death in patients with high cholesterol

Sildenafil does not help heart failure patients with preserved ejection fraction

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News